ABEO
Abeona Therapeutics Inc
Abeona Therapeutics Inc
$ABEO Reports Decreased Costs and Progress Towards BLA Submission for its EB-101 Therapy for RDEB in Q1 2023 Financial Results
Abeona Therapeutics presented its Q1 2023 financial results and indicated decreased costs compared to last year. The company aims to submit a Biologics License Application for its cell therapy product, EB-101, in late 2Q or early 3Q 2023. Abeona's VIITAL study further demonstrated EB-101's value in treating RDEB. The company will present proof-of-concept data from its AAV ophthalmology program at ASGCT's 26th Annual Meeting. Abeona is confident that its cash and cash equivalents can fund its operations until Q3 2024 and will hold a conference call on May 23, 2023, to provide further updates.
4mo ago
$ABEOAbeona Therapeutics Inc
$ABEO reports positive Phase 3 results and plans for BLA submission
Abeona Therapeutics reports positive results for Phase 3 VIITAL study of EB-101 in epidermolysis bullosa, plans to submit Biologics License Application leveraging these results. The company also continues progress with AAV-based gene therapy options for other diseases. 2022 revenues at $1.4M, resources to support operations until Q3 2024. As a financial analyst, this information provides insight into Abeona's current activities and potential for growth.
6mo ago
$ABEO